Lixte Biotechnology Holdings Inc (LIXT)
1.907
+0.05
(+2.53%)
USD |
NASDAQ |
Sep 27, 16:00
1.90
-0.01
(-0.37%)
After-Hours: 20:00
Lixte Biotechnology Holdings SG&A Expense (Annual): 4.192M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.192M |
| December 31, 2022 | 4.962M |
| December 31, 2021 | 4.984M |
| December 31, 2020 | 2.043M |
| December 31, 2019 | 1.649M |
| December 31, 2018 | 2.097M |
| December 31, 2017 | 1.342M |
| December 31, 2016 | 1.265M |
| December 31, 2015 | 0.7544M |
| December 31, 2014 | 1.285M |
| Date | Value |
|---|---|
| December 31, 2013 | 0.495M |
| December 31, 2012 | 1.094M |
| December 31, 2011 | 0.5334M |
| December 31, 2010 | 0.4361M |
| December 31, 2009 | 1.054M |
| December 31, 2008 | 0.6642M |
| December 31, 2007 | 1.235M |
| December 31, 2006 | 0.269M |
| December 31, 2005 | 0.0329M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
1.649M
Minimum
2019
4.984M
Maximum
2021
3.566M
Average
4.192M
Median
2023
SG&A Expense (Annual) Benchmarks
| Soligenix Inc | 4.483M |
| Tonix Pharmaceuticals Holding Corp | 34.75M |
| Shuttle Pharmaceuticals Holdings Inc | 2.375M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 15.29M |